近年来随着治疗靶点的发现和新型靶向药物的不断研发，肿瘤治疗已步入精准治疗新时代。近日，2024 年世界肺癌大会（WCLC）和欧洲肿瘤内科学会（ESMO）年会陆续召开，带来肿瘤领域最新前沿进展。会议中，针对 BRAF、MET 14 ...

诺和诺德因减肥药价格问题面临美参议院质询。9月23日，美国参议院网站显示，美参议院将于当地时间9月24日举行听证会，审查诺和诺德是否为糖尿病和肥胖患者提供价格过高的司美格鲁肽产品Ozempic和Wegovy。强生EGFR/c-MET双抗再获批准。9月20日，强生宣布，FDA已批准其EGFR/c-MET双抗Rybrevant与标准化疗，联合治疗在接受EGF ...

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

历经多年不懈探索，奥希替尼在 EGFR 突变 NSCLC 治疗领域不断突破，至今已 8 次荣登 NEJM，成为其传奇历程的见证。与此同时，奥希替尼的应用范围不断扩大，从晚期扩展到早期，从后线治疗走向前线治疗，从单药治疗到联合治疗，其在国内已有 4 个适应症获批上市，是目前国内适应症范围最广*的 EGFR-TKI。而且，奥希替尼是目前唯一*的一线、二线及辅助治疗适应症均纳入医保的三代 ...

Discover AstraZeneca's groundbreaking patent for dual-target antibody molecules aimed at EGFR and c-Met, paving the way for innovative cancer therapies.

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...